Valerio Therapeutics
ALVIO
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.
Contact
49 Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
38
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,399.80 | 30.50 | 0.36% |
| CAC 40 | 7,696.92 | 31.01 | -0.40% |
| DAX 40 | 23,249.65 | 94.89 | -0.41% |
| Dow JONES (US) | 40,829.00 | 389.83 | -0.95% |
| FTSE 100 | 8,576.51 | 20.91 | -0.24% |
| HKSE | 22,791.71 | 129.00 | 0.57% |
| NASDAQ | 17,689.66 | 154.58 | -0.87% |
| Nikkei 225 | 36,779.66 | 51.03 | -0.14% |
| NZX 50 Index | 12,496.89 | 75.80 | 0.61% |
| S&P 500 | 5,606.91 | 43.47 | -0.77% |
| S&P/ASX 200 | 8,178.30 | 26.90 | 0.33% |
| SSE Composite Index | 3,340.10 | 23.99 | 0.72% |